Evidence map›Paper›PMID 37212484›Full record

Trial reportCancer medicine2023

A nurse-led intervention in patients with newly diagnosed cancer and Type 2 diabetes: A pilot randomized controlled trial feasibility study.

Lisa Scarton, Tarah Nelson, Ara Jo, LaToya J O'Neal, Yingwei Yao, Shavondra Huggins, Anatolia B Legaspi, Mariah J McClaren, Jake S Cabassa, Joan M Burgos Melendez and 6 more

Open access · goldFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 1 country.

Lisa ScartonCollege of Nursing, University of Florida, Gainesville, Florida, USA.ORCID 0000-0003-1255-0811
Tarah NelsonCollege of Nursing, University of Florida, Gainesville, Florida, USA.ORCID 0000-0003-3080-8847
Ara JoCollege of Public Health and Health Professions, University of Florida, Gainesville, Florida, USA.
LaToya J O'NealCollege of Agricultural and Life Sciences, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, Florida, USA.
Yingwei YaoCollege of Nursing, University of Florida, Gainesville, Florida, USA.
Shavondra HugginsCollege of Nursing, University of Florida, Gainesville, Florida, USA.
Anatolia B LegaspiCollege of Pharmacy, University of Florida, Gainesville, Florida, USA.
Mariah J McClarenCollege of Nursing, University of Florida, Gainesville, Florida, USA.
Jake S CabassaCollege of Nursing, University of Florida, Gainesville, Florida, USA.
Joan M Burgos MelendezCollege of Nursing, University of Florida, Gainesville, Florida, USA.
Juan M Munoz-PenaDivision of Endocrinology, Diabetes and Metabolism, University of Florida College of Medicine, Gainesville, Florida, USA.
Merry J MarkhamDivision of Hematology and Oncology, University of Florida, College of Medicine, Gainesville, Florida, USA.
Martina C MurphyDivision of Hematology and Oncology, University of Florida, College of Medicine, Gainesville, Florida, USA.
Jonathan A ChatzkelDivision of Hematology and Oncology, University of Florida, College of Medicine, Gainesville, Florida, USA.
Sherise RogersDivision of Hematology and Oncology, University of Florida, College of Medicine, Gainesville, Florida, USA.
Thomas J GeorgeDivision of Hematology and Oncology, University of Florida, College of Medicine, Gainesville, Florida, USA.ORCID 0000-0002-6249-9180
University of Florida · USUniversity of Florida Health · US

Funding

Tissue Modeling and Drug Development Core (TMDDC) Shared ResourceU54CA233465 · UNIVERSITY OF SOUTHERN CALIFORNIA · 2025 to 2025
$1.1M
Tissue Modeling & Drug Development Shared Resources CoreU54CA233444 · UNIVERSITY OF FLORIDA · 2025 to 2025
$1.1M
Tissue Modeling and Drug Discovery CoreU54CA233396 · FLORIDA AGRICULTURAL AND MECHANICAL UNIV · 2025 to 2025
$1.0M
NCI NIH HHS U54 CA233396NCI NIH HHS U54 CA233444NCI NIH HHS U54 CA233465
6 · The paper itself

Abstract

backgroundUndiagnosed Type 2 diabetes (T2D) has been associated with advanced stage cancer at diagnosis, higher mortality, and lower long-term all-cause survival. This was a RCT pilot study to examine the feasibility of a nurse-led T2D intervention for adults with newly diagnosed cancer (≤3 months), and T2D, undiagnosed or untreated with medication, conducted at an outpatient oncology clinic affiliated with a large academic institution.

methodsParticipants needed to meet the eligibility criteria including a HbA1c level between 6.5% and 9.9%. Randomization was 1:1 to a 3-month intervention that consisted of nursing-led diabetes education and immediate initiation of metformin versus referral to primary care for usual care (control).

resultsThree hundred and seventy nine patients were screened using EHR, 55 agreed to participate, and 3 had eligible HbA1c levels and were randomized in the study. Primary reasons for study exclusion included life expectancy ≤2 years (16.9%), current use or inability to tolerate metformin (14.8%), and abnormal labs that contraindicated metformin use (13.9%).

conclusionThis study was not feasible due to recruitment inefficiencies, but acceptable to all who qualified.

Indexed as

Diabetes Mellitus, Type 2MetforminNeoplasmsAdultFeasibility StudiesGlycated HemoglobinHumansNurse's RolePilot ProjectsGlycated HemoglobinMetforminclinical managementclinical trialscommunity outreachmedical oncologyscreening

Identifiers

PMID37212484
PMCPMC10278510
OpenAlexW4377220120

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.